ArticlesRepair of the lower and middle parts of the face by composite tissue allotransplantation in a patient with massive plexiform neurofibroma: a 1-year follow-up study
Introduction
The risk to benefit ratio of face transplantation using a composite tissue allograft (CTA) remains debatable,1 although the procedure seems to be technically feasible. However, reports of cases that have assessed the risk to benefit ratio of the procedure are rare.2 The need for large doses of immunosuppressive drugs to ensure CTA survival and the need for intense psychological support to prevent distress has raised ethical concerns, preventing many teams from attempting this type of transplant.
Most facial defects can be reconstructed using autologous tissues and standard plastic surgery techniques. However, in some cases, conventional plastic and reconstructive surgery cannot provide satisfactory results to severely disfigured patients. The patients concerned have generally been disfigured by burns, ballistic trauma, tumours, or congenital deformities.3 Congenital deformities can have a genetic origin, as in the case of neurofibromatosis type 1 (NF1), which is an autosomal dominant genetic disease with an incidence of 1 in 2500–3300.4 Plexiform neurofibromas associated with NF1 occur in about 10% of cases, can be disfiguring, and have a major effect on quality of life.5 Conventional surgery often has little to offer patients with these conditions, and face transplantation has been identified as a possible alternative treatment. We report here a 1-year follow-up of a patient with deforming plexiform neurofibroma associated with NF1 who underwent face transplantation with a CTA. We focus on the management of post-transplantation immunosuppression and on functional and psychosocial outcomes.
Section snippets
Methods
In 2002, we asked the French National Ethics Advisory Committee for Life Sciences and Health to give advice about facial repair using a CTA. The committee's response was delivered in 2004: this kind of transplant could be proposed for severely disfigured patients—cases of total destruction of the mouth and the nose for example—and should be presented to the patient as highly experimental. Preclinical anatomical studies had already been done to optimise the surgical technique.6, 7 A clinical
Results
The only postoperative complication seen was transient steroid-induced confusion, which was treated with 25–50 mg of chlorpromazine for 5 days. The swelling resolved within 1 week. The tracheotomy cannula was removed on day 8 and the patient was able to speak and eat by day 10.
The follow-up immunosuppressive regimen is described in figure 3. Early biopsies of skin and mucosa (days 2, 7, 14, and 21) showed no lymphocyte infiltration, corresponding to grade 0 on the acute rejection scale. Mild
Discussion
Our case confirms that face transplantation is surgically feasible and effective for the correction of specific disfigurement, due in this case to a genetic disorder. The procedure involved three technical challenges: the removal of a disfiguring tumour, plexiform neurofibroma, which is difficult to debulk due to its vascularity;10 the need to procure the face of a donor with a beating heart; and the transplantation itself.
Blood loss is a known, life-threatening complication of surgery for
References (23)
- et al.
Facial transplantation: a comprehensive review of the literature
J Oral Maxillofac Surg
(2006) - et al.
[Face allotransplantation: anatomical study, potential partial and total facial allografts harvesting and clinical application]
Ann Chir Plast Esthet
(2007) Neurofibromatosis of the skull base
Clin Plast Surg
(1995)- et al.
Venous aneurysm, arterial dysplasia, and near-fatal hemorrhages in neurofibromatosis type 1
Hum Pathol
(1996 Sep) - et al.
Long-term deterioration of kidney allograft function
Am J Transplant
(2005) - et al.
First human face allograft: early report
Lancet
(2006) - et al.
Human hand transplantation: what have we learned?
Transplant Proc
(2004) - et al.
The course of neurofibromatosis type 1 on immunosuppression after lung transplantation: report of 2 cases
J Heart Lung Transplant
(2004) - et al.
Outcomes 18 months after the first human partial face transplantation
N Engl J Med
(2007) - et al.
Face transplantation: where do we stand?
Plast Reconstr Surg
(2004)
The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2
JAMA
Cited by (243)
Modified facelift in severe plexiform neurofibromatosis associated with venous vascular malformation: Case report
2023, Annales de Chirurgie Plastique EsthetiqueFacial Transplantation
2022, Facial Plastic Surgery Clinics of North AmericaPatient-reported outcomes measures used in facial vascularized composite allotransplantation: A systematic literature review
2022, Journal of Plastic, Reconstructive and Aesthetic SurgeryPathologies of oral and sinonasal mucosa following facial vascularized composite allotransplantation
2021, Journal of Plastic, Reconstructive and Aesthetic SurgeryMandibular allotransplant procedures in dogs with the immunosuppressive agent FK506
2021, Journal of Oral and Maxillofacial Surgery, Medicine, and PathologyFirst human facial retransplantation: 30-month follow-up
2020, The Lancet
- ‡
These authors contributed equally